Specify a stock or a cryptocurrency in the search bar to get a summary
Orchestra BioMed Holdings Inc.
OBIOOrchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania. Address: 150 Union Square Drive, New Hope, PA, United States, 18938
Analytics
WallStreet Target Price
15.6 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures OBIO
Dividend Analytics OBIO
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History OBIO
Stock Valuation OBIO
Financials OBIO
Results | 2019 | Dynamics |